{"classes":[{"categories":[{"measurements":[{"comment":"Median DOR not reached by the time of the data cutoff (24-Aug-2018). DOR upper limit not calculated due to no progressive disease by the time of last disease assessment.","groupId":"OG000","lowerLimit":"1.4","upperLimit":"NA","value":"NA"},{"comment":"DOR upper limit not calculated due to no progressive disease by the time of last disease assessment.","groupId":"OG001","lowerLimit":"1.1","upperLimit":"NA","value":"15.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"256"},{"groupId":"OG001","value":"153"}],"units":"Participants"}],"description":"DOR was defined as the time from first documented evidence of a Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1 until progressive disease (PD) or death due to any cause, whichever occurred first. PD was defined per RECIST 1.1 as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The DOR was calculated using the product-limit (Kaplan-Meier) method for censored data. The DOR for all participants who experienced a CR or PR is presented.","dispersionType":"Full Range","groups":[{"description":"Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.","id":"OG000","title":"Pembrolizumab + Axitinib"},{"description":"Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.","id":"OG001","title":"Sunitinib"}],"paramType":"MEDIAN","populationDescription":"The analysis population consisted of all randomized participants who experienced a CR or PR.","reportingStatus":"POSTED","timeFrame":"Through Database Cutoff Date of 24-Aug-2018 (up to approximately 22 months)","title":"Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Imaging Review","type":"SECONDARY","unitOfMeasure":"Months"}